Results from a phase 3 clinical trial published in the New England Journal of Medicine, today (June 2nd) show that patients ...

CHICAGO -- For the first time in a phase III trial, overall survival (OS) in unresectable pancreatic cancer improved ...

Jazz Pharmaceuticals' study shows Zepzelca with atezolizumab boosts survival in small cell lung cancer, cutting progression ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad eligibility criteria, and reduced data collection, has quickly answered its primary ...

The SWOG S2302 Pragmatica-Lung trial, which broke new ground with its streamlined pragmatic design, unusually broad ...

Shares of Amgen (AMGN) were in the spotlight on Monday morning after the company announced that its immunotherapy Imdelltra ...

Amgen said interim results from a Phase 3 trial showed Imdelltra reduced the risk of death and other benefits for patients with small cell lung cancer.

Amgen has detailed a positive phase 3 readout for its T-cell engager Imdelltra in previously treated small cell lung cancer ...

Amgen's Imdelltra reduced the risk of death by 40% compared to chemotherapy for small cell lung cancer patients whose disease ...

Key Takeaways Wildfire smoke decreases lung cancer patients’ odds of survivalCalifornians with lung cancer had a 20% ...